FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson's disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer's disease. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.